Bayer's Dual Bet: A €375 Million Pharma Hand-Off and the Missouri Ruling That Could Redraw the Map
Published on 09/23/2026 at 04:30 | Editorial boerse-global.de
Bayer's pharmaceutical division is being reshaped on two fronts at once — one voluntary, one not. The voluntary side came into focus this week with the sale of the cancer drug Stivarga to fellow German pharma group Grünenthal, a transaction that could generate total proceeds of up to EUR 375 million for the Leverkusen-based company. The involuntary side remains parked in a Missouri courtroom, where a judge has yet to sign off on a $7.25 billion settlement covering the long-running Roundup cancer litigation.
The Stivarga deal, announced yesterday, hands Grünenthal the rights to the oncology treatment, with Bayer's consideration structured as an upfront payment plus success-based milestone payments that could top out at the EUR 375 million figure. Market reaction was measured but positive: Bayer shares changed hands at EUR 49.54 today, a gain of 0.8% on the session. The move fits a familiar pattern for the conglomerate — passing mature medicines to specialist partners frees up administrative and marketing capacity, allowing Bayer to channel resources toward higher-margin products and newer active ingredients. Crucially, the milestone structure means Bayer retains a slice of Stivarga's future earnings potential rather than severing ties entirely.
A Regulatory Hot Streak in Specialty Medicine
While the divestment trims the portfolio's older layer, Bayer's pipeline has been delivering fresh approvals at a steady clip. On September 17, the FDA granted Finerenon — marketed as Kerendia — an additional indication for adults with chronic kidney disease linked to type-1 diabetes. According to Bayer, this marks the first therapy approved by the US regulator for that patient group in more than three decades, and it is the third green light the drug has received overall.
Eight days earlier, on September 9, the FDA handed accelerated approval to Sevabertinib, a targeted therapy cleared as a first-line option for adults with HER2-mutated non-small cell lung cancer. Both drugs bolster Bayer's position in high-margin specialty areas, and both arrived within a fortnight of each other — a cadence that gives the pharma unit rare forward momentum.
Should investors sell immediately? Or is it worth buying Bayer?
The agricultural arm, Crop Science, has been moving in parallel. Commercial rollout of Plenexos and the Preceon Smart Corn System began on September 15. Further out, Bayer plans to launch Vyconic in the US and Canada next year, with Intacta 5+ slated for the Brazilian planting season of 2027/2028. Partnerships are part of the push: a September 9 commercial agreement with Neste aims to scale newgold winter rapeseed for biofuel production, and on September 17, Robigo and Leaps by Bayer announced financing to advance microbial solutions against fungal diseases in soybeans.
The Missouri Decision Looms Over Everything
None of that pipeline progress, however, resolves the question that has shadowed Bayer's equity story for years. Monsanto, the subsidiary at the center of the glyphosate litigation, filed a motion on September 14 with a Missouri court seeking approval of a $7.25 billion settlement designed to close out the Roundup cancer claims. A hearing on final approval was held the same day before the Missouri Circuit Court, but a formal ruling has not yet been issued — the judge's decision is expected at a later date.
The stakes are hard to overstate. Bayer currently faces roughly 65,000 lawsuits across US federal and state courts. A green light from the bench would chart a path toward resolving that entire backlog. A rejection, or a demand for substantial revisions, would leave the legal flank wide open, forcing the company back into protracted, costly case-by-case litigation — with the added threat of unpredictable jury awards draining further billions.
That outcome would also cast a shadow over the operational wins. Positive contributions from Finerenon and Sevabertinib could be swallowed by new provisions or settlement costs, while investors might grow warier as product cycles such as Vyconic and Intacta 5+ require upfront investment before they generate meaningful returns.
What the Chart Says — and What It Can't Price
From a technical standpoint, the picture remains constructive as long as the stock trades above its 200-day moving average of EUR 42.58. A rejection in Missouri would likely trigger profit-taking and pressure the share price, leaving the stock without the foundation for a sustained breakout. The shares have already climbed 34% since the start of the year, a run that reflects both the pipeline progress and hopes for a legal clean slate.
That makes the pending ruling the single most concrete catalyst on the horizon. Investors will be watching closely to see whether the court accepts the settlement as drafted or sends the parties back to the negotiating table. Either way, the decision will set the direction for the months ahead — and determine whether Bayer's operational momentum finally gets the stage it has been waiting for.
Ad
Bayer Stock: New Analysis - 23 September
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
